Greenwich Lifesciences Stock Today
| GLSI Stock | USD 11.61 0.60 4.91% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Greenwich Lifesciences is trading at 11.61 as of the 18th of March 2025. This is a 4.91 percent decrease since the beginning of the trading day. The stock's open price was 12.21. Greenwich Lifesciences has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of September 2020 | Category Healthcare | Classification Health Care |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. The company has 13.14 M outstanding shares of which 653.14 K shares are currently shorted by private and institutional investors with about 31.07 trading days to cover. More on Greenwich Lifesciences
Moving together with Greenwich Stock
| 0.7 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Greenwich Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Greenwich Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGreenwich Lifesciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Greenwich Lifesciences' financial leverage. It provides some insight into what part of Greenwich Lifesciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Greenwich Lifesciences (GLSI) is traded on NASDAQ Exchange in USA. It is located in Building 14, Stafford, TX, United States, 77477 and employs 3 people. Greenwich Lifesciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 160.5 M. Greenwich Lifesciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 13.14 M outstanding shares of which 653.14 K shares are currently shorted by private and institutional investors with about 31.07 trading days to cover.
Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check Greenwich Lifesciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Greenwich Lifesciences is $160.5 Million. Greenwich Lifesciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Greenwich Ownership Details
Greenwich Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Strs Ohio | 2024-09-30 | 12.8 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 11.2 K | |
| Barclays Plc | 2024-12-31 | 9.6 K | |
| Bank Of America Corp | 2024-12-31 | 7.3 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 7.1 K | |
| Ubs Group Ag | 2024-12-31 | 6.6 K | |
| Rhumbline Advisers | 2024-12-31 | 6.5 K | |
| New York State Common Retirement Fund | 2024-12-31 | 6 K | |
| Citigroup Inc | 2024-12-31 | 4.9 K | |
| Blackrock Inc | 2024-12-31 | 357.8 K | |
| Vanguard Group Inc | 2024-12-31 | 275 K |
Greenwich Lifesciences Historical Income Statement
Greenwich Stock Against Markets
Greenwich Lifesciences Corporate Management
| Christine Fischette | VP Development | Profile | |
| Snehal Patel | CFO CEO | Profile | |
| Eric Rothe | Founder Director | Profile | |
| Frank MD | Chief Director | Profile | |
| Jaye Thompson | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.